Retatrutide in New Mexico: Trial-registry Status and Research Records

At a glance

• Review question / What do federal sources and ClinicalTrials.gov records establish about retatrutide in New Mexico?
• Best evidence / federal status and trial-registry records
• Evidence snapshot / 2026-08-09
• Commercial status / no FDA-approved product or ordinary retail supply
• HealthRX role / independent educational review; no retatrutide product or treatment offer

Direct answer

Retatrutide is not commercially available in the state. In the 2026-08-09 ClinicalTrials.gov snapshot, 1 retatrutide study record listed at least one location in New Mexico. Example identifiers were NCT07165028. A location listing can describe a completed, active, or planned site; it does not establish current recruitment, eligibility, public supply, or commercial availability.

The wording here is deliberately evidence-specific. “A study exists,” “a registry lists a site,” and “a paper reports an endpoint” are different statements from “a product is approved,” “a treatment works,” or “a person should use it.” This page makes only the first type of statement and links the controlling source.

Evidence map for trial-registry status in New Mexico

How HealthRX evaluated this question

ClinicalTrials.gov is a registry, not a pharmacy directory. Location modules can include sites for completed, active, or planned studies and can change after a record is posted. HealthRX reviewed the registry-level state field, record identifier, and snapshot date—not private eligibility information or unverified third-party trial listings.

For this page, HealthRX asked: (1) Is trial-registry status in New Mexico named in the protocol or publication? (2) Was it a prespecified endpoint, eligibility factor, subgroup, or only background context? (3) Is the record complete, current, and peer reviewed? (4) Does an FDA action or approved label exist? That sequence prevents a research observation from being rewritten as a product claim.

Evidence checks specific to this record

Assessment window

Record when the relevant measurement was collected and how long participants were observed. An early pharmacology window, a fixed treatment period, and extended follow-up answer different questions about trial-registry status in New Mexico; they should not be blended into one timeless conclusion.

Endpoint definition

Use the protocol's exact definition, unit, assessment method, and analysis time. Similar-sounding endpoints can measure different constructs. For trial-registry status in New Mexico, a change in wording, threshold, or time point may materially change the research question.

Source version

ClinicalTrials.gov records can change as recruitment, locations, outcomes, and completion dates are updated. Record the review date for trial-registry status in New Mexico, inspect the change history, and let the current primary record control over an older search snippet or copied summary.

Outcome completeness

Look for the full participant flow, all prespecified outcomes, adverse-event tables, withdrawals, protocol deviations, and appendices—not only an abstract. Selective fragments can create a distorted view of trial-registry status in New Mexico even when every quoted number is technically accurate.

Sponsor and author roles

Identify the sponsor, funding, author affiliations, data access, and stated conflicts. These facts do not invalidate a study, but they help readers evaluate independent replication, analytic transparency, and how confidently trial-registry status in New Mexico can be generalized.

What remains unresolved

Federal approval and compounding status do not change by state. A New Mexico location in a study record is research metadata, not a retail listing, prescription pathway, price, insurance benefit, or HealthRX offering.

The source hierarchy also matters. An FDA action controls approval status. ClinicalTrials.gov controls the public registry record. A peer-reviewed report can describe study methods and observations. A press release, seller page, social post, search result, or anecdote cannot replace those sources.

What evidence could change the answer

Readers evaluating a registry record should check its current overall status, site status, eligibility criteria, last update date, sponsor, and official contact fields directly on ClinicalTrials.gov.

Any new result should be read with its protocol and statistical analysis plan. Important checks include enrollment, prespecified outcomes, follow-up duration, missing-data handling, multiplicity, participant flow, sponsor involvement, and whether the finding has undergone peer review and regulatory review.

Current federal and commercial status

Retatrutide remains investigational. No retatrutide product is FDA-approved for any indication or available through ordinary commercial prescription or retail sale. FDA states that retatrutide cannot be used in compounding under federal law. HealthRX does not offer it. FDA's current statement says retatrutide is not a component of an FDA-approved drug and cannot be used in compounding under federal law. A ClinicalTrials.gov study or eligibility-limited expanded-access record is not commercial approval, ordinary prescribing, retail availability, or evidence that HealthRX offers the investigational substance.

Federal regulation distinguishes scientific exchange from promotion: it does not restrict full exchange of scientific information, but it does restrict representing an investigational drug as safe or effective in a promotional context and precludes commercialization before approval.

Source selection and review method

HealthRX reviewed primary or primary-index sources current to 2026-08-09: ClinicalTrials.gov record NCT05929066; ClinicalTrials.gov record NCT04881760; ClinicalTrials.gov pre-approval expanded-access record NCT07629401; FDA status statement for unapproved GLP-1 drugs; 21 CFR 312.7, Promotion of investigational drugs. Sources were selected because they control regulatory status, register a study, or index a peer-reviewed clinical report. The review reports study design and evidence limits without reproducing promotional outcome claims or converting protocols into patient instructions.

Frequently asked questions

›Does a study location mean retatrutide is available for prescription?

No. A ClinicalTrials.gov location is research metadata. It does not establish commercial supply, ordinary prescribing, pharmacy dispensing, insurance coverage, or eligibility for a study.

›Can state law make compounded retatrutide permissible?

FDA states that retatrutide cannot be used in compounding under federal law. A state location does not change that federal status.

›How current is the trial-registry status in New Mexico review?

HealthRX checked FDA, federal-regulation, publication, and ClinicalTrials.gov records on 2026-08-09. Registry locations and study statuses can change, so the linked primary record controls.

References

1. ClinicalTrials.gov. TRIUMPH-1 registry record. 2026. https://clinicaltrials.gov/study/NCT05929066
2. ClinicalTrials.gov. Phase 2 obesity-study registry record. 2026. https://clinicaltrials.gov/study/NCT04881760
3. ClinicalTrials.gov. Pre-approval expanded-access registry record. 2026. https://clinicaltrials.gov/study/NCT07629401
4. U.S. Food and Drug Administration. FDA status statement for unapproved GLP-1 drugs. 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
5. Electronic Code of Federal Regulations. 21 CFR 312.7, Promotion of investigational drugs. 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-312/subpart-A/section-312.7